drugset / Trial / NCT00003389

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

NCT00003389

RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining more than one drug with radiation therapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is most effective in treating Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well they work, with or without radiation therapy, in treating patients with Hodgkin's lymphoma.

Timeline

Start
1999-06-17
Primary completion
2011-09
Completion
2016-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bleomycin Unknown 5 iu Intravenous
Subject Bleomycin Unknown 10 iu Intravenous
Comparator Cyclophosphamide Other / unclassified 375 mg/m2 Intravenous
Subject Dacarbazine Small molecule 375 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 25 mg/m2 Intravenous
Comparator Etoposide Small molecule 60 mg/m2 Intravenous
Comparator Prednisone Other / unclassified 40 mg/m2 Oral
Subject Vinblastine Small molecule 6 mg/m2 Intravenous
Comparator Vincristine Small molecule 1.4 mg/m2 Intravenous
Comparator mechlorethamine Small molecule 6 mg/m2 Intravenous

Indications